Phase 2 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with multiple myeloma, confirmed using the 2016 International Myeloma Working Group diagnostic standards.
- People whose multiple myeloma has come back, gotten worse, or who were unable to tolerate at least one previous treatment for the disease.
- People who have measurable signs of the disease at the time of screening, shown by at least one of the following: a certain level of an abnormal protein (M-protein) in the blood or urine, or an abnormal level of specific proteins called free light chains in the blood (confirm specific thresholds with trial site).
Who may not be able to join:
- People who have previously had a severe (Grade 3 or higher) immune reaction called cytokine release syndrome linked to certain types of cancer immunotherapy, such as CAR-T cell therapy or similar treatments.
- People who have previously received a therapy that specifically targets a protein called GPRC5D.
- People who received genetically modified cell therapies (such as CAR-T or NK cell therapy) within the past 3 months.
- People who received certain targeted therapies, experimental drugs, or experimental medical devices within the past 21 days or within a specific timeframe based on how long the drug stays in the body, whichever is longer (confirm with trial site).
- People who received a type of treatment called bispecific antibody therapy for multiple myeloma within the past 21 days or a specific timeframe based on how long the drug stays in the body, whichever is longer.
- People who received chemotherapy or monoclonal antibody treatments within the past 21 days.
- People who received a type of treatment called a proteasome inhibitor within the past 14 days.
- People who received a type of treatment called an immunomodulatory drug within the past 7 days.
- People who received radiation therapy within the past 14 days, unless it was a low-dose treatment aimed at managing symptoms.
- People who previously could not tolerate the drug Pomalidomide, if applying for a treatment group that includes Pomalidomide.
- People who previously could not tolerate the drug Bortezomib, if applying for a treatment group that includes Bortezomib.
- People who previously could not tolerate the drug Lenalidomide, if applying for a treatment group that includes Lenalidomide.
- People who previously could not tolerate the drug Daratumumab, if applying for a treatment group that includes Daratumumab.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 008613502181109
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
ORR (Partial Response [PR] or Better); Overall Minimal Residual Disease (MRD)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.